Major hepatic resection may suppress the growth of tumours remaining in the residual liver by Yokoyama, H et al.
Liver resection for hepatocellular carcinoma (HCC), which is one
of the most common malignant tumours, is still considered as the
most radical treatment. Recent advances in surgical techniques for
hepatectomy have made surgical intervention a safe and effective
treatment for HCC. However, even if the resection is curative,
recurrences in the remaining liver frequently occur (Nagao et al,
1990; Yamamoto et al, 1996). Once such recurrences are found,
the patient prognosis is poor. In reality, the overall 5 year survival
rate of patients with HCC after curative resection has been
reported to exceed fifty per cent (Kosuge et al, 1993). Therefore,
the prevention of recurrences is important for patients with HCC,
however the mechanisms of such recurrences remain unclear.
When HCC patients are operated upon, intra-operative manipu-
lation should be as careful as possible in order not to mechanically
disperse any possible cancer cells (Ezaki et al, 1989). Despite such
careful manipulation, residual microscopic HCC cells undetected
by pre-operative imaging for diagnosis, can cause recurrences
(Utsunomiya et al, 1992). Other investigators have shown that
most recurrent tumours occurred predominantly in the remaining
liver near the primary lesion rather than in distant segments
(Nagao et al, 1990; Yamamoto et al, 1996). Further, most
secondary tumours in the remaining liver after the first hepatic
resection were considered to be caused by metastatic recurrence
and not by secondary carcinogenesis, the so-called ‘multicentric
occurrence’ (Shimada et al, 1998). These reports allow us to spec-
ulate that the most likely causes of HCC recurrence may be due to:
(a) the cancer cells dispersed by intra-operative manipulation and
(b) existence of HCC in the remaining liver following curative
resection, which is the established tumour undetected pre-
operatively.
Several experiments for acceleration of intra-hepatic tumour
growth by partial hepatectomy in animal models have been trying
to prove how cancer cells are distributed in the liver following
hepatectomy in conjunction with the above explanation (a)
(Mizutani et al, 1992; Slooter et al, 1995; Picardo et al, 1998).
However, it is still controversial as to whether partial hepatic
resection renders progression or regression of tumour cells (Ono et
al, 1986; Castillo et al, 1989). The different timing of hepatectomy
before or after administration of different tumour cell lines, via
different routes, may cause inconsistent results for these experi-
mental studies. Additionally, very few studies have reported the
effect of hepatectomy on established HCC in the residual liver as
outlined above in point (b). In the present study using an intra-
hepatic tumour implantation model, the effects of hepatic resection
on the growth of the established tumour in the remaining liver
were investigated and discussed from the aspect of apoptosis.
MATERIALS AND METHODS
Animals
Adult male Donryu rats (Charles River Japan, Inc., Yokohama,
Japan), 6–7 weeks old, weighing 170–245 g were housed in indi-
vidual cages with a 12-hour light–dark cycle and provided with tap
water and a standard laboratory diet ad libitum before and after
operation. All operations were performed under ether anaesthesia.
This study was approved by the Animal Studies Committee of
Oita Medical University, Japan and performed under the National
Institutes of Health Standards of Animal Care.
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Tumour cell line
The AH-130 rat ascites hepatoma cell line (a gift from Taiho
Pharmaceutical Co., Ltd., Tokyo, Japan) was maintained by intra-
peritoneal passage in male Donryu rats every 7–8 days. A suspen-
sion of the AH-130 tumour cells obtained from ascites was
prepared in Hanks’ balanced salts solution (HBSS) at a concentra-
tion of 5 × 106 cells/ml and 1 ml injected into the flank of Donryu
rats. One week later, the subsequent subcutaneous solidified
tumour was used for further experiments.
Intra-hepatic tumour implantation
We have modified a technique of intra-hepatic tumour implanta-
tion (Yang et al, 1992). A brief outline of our modifications is as
follows. A small cube about 1 mm3 of tumour fragment was
prepared by sharply mincing a 1-week-old vital outer zone sub-
cutaneous growth of the tumour. The randomization followed the
tumour implantation. A small incision on the median lobe of the
liver was made using the tip of a No. 11 surgical blade, and the
1m m 3 of tumour was gently inserted into the incision through an
18-gauge i.v. catheter (Terumo, Tokyo, Japan) with blunted tip. A
small piece of Gelfoam (Upjohn, Tokyo, Japan) was used before
and after the tumour insertion respectively. These modifications
enabled us to bury the tumour fragment into the incision with
haemostasis and without intra-peritoneal tumour cell leakage.
Preliminary experiments have shown that a 1 mm3 tumour frag-
ment has reliably lodged in 100% of hepatic parenchyma five days
after tumour implantation. This lodged tumour has grown to
approximately 2 mm in diameter (data not shown). Based on this
observation, 5 days following tumour implantation was used as the
time for subsequent experiments.
Experimental design
85 rats which underwent the intra-hepatic tumour implantation,
were randomly allocated to the following three groups: sham
operation group, 30% hepatectomy group, 60% hepatectomy
group. Sham operations on controls consisted of laparotomy and
gentle manipulation of the liver. 30% hepatectomy was performed
by resecting the right lateral and caudate lobes of the liver. 60%
hepatectomy included resection of the left lateral, right lateral, and
caudate lobes of the liver by a modified method of Higgins and
Anderson (1931). All animals following surgery received 10 ml
normal saline solution intra-peritoneally for volume resuscitation
and ceftriaxone sodium (Roche, Basel, Switzerland) 20 mg/body
intramuscularly at the end of the procedure.
Evaluation of tumour growth, body weight gain and
liver regeneration rate
On post-operative day (POD) 7, ten rats from each group were
weighed and then sacrificed after sampling whole blood from the
inferior vena cava. After whole wet livers were harvested and
weighed, the tumour and non-tumour portions were separated and
weighed respectively. Moreover, the body weight gain and the
liver regeneration rate were calculated.
Evaluation for apoptosis
For liver sampling from each group on POD 7, non-tumour
portions were obtained from the median lobe keeping
approximately 1 cm away from tumour, and the tumour portion
was dissected free from the normal hepatic parenchyma. These
specimens were immersed in liquid nitrogen immediately after
sampling and then stored at –80° C until analysed. For determina-
tion of DNA fragmentation on gel electrophoresis (Wyllie, 1980),
the DNA ZOL® Reagent (GIBCO BRL, Grand Island, NY, USA)
was used to extract the DNA. 20 µ g of the isolated DNA was
electrophoresed in a 2.0% agarose gel. The gel was stained with
0.5 µ g/ml ethidium bromide for 15 min, destained with water for
1 hour and visualized under UV light. For TUNEL (terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end
labelling) assay (Gavrieli et al, 1992) using the liver tissue on POD
7, liver specimens which were collected from 4 rats per each
group, were formalin-fixed, paraffin-embedded and sectioned at
5 µ m thickness. We used a DeadEnd™ Colorimetric Apoptosis
Detection System (Promega Corporation, Madison, WI, USA)
according to the manufacturer’s instructions for the modified
TUNEL assay. After staining with diaminobenzidine (DAB), the
specimens were counterstained with haematoxylin, dehydrated
and mounted. The apoptotic indices (AI) were calculated for each
sample by counting the number of TUNEL-positive tumour cells
divided by the total counted number of tumour cells.
Approximately two thousand tumour cells were counted for each
intra-hepatic tumour.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
RT-PCR was performed basically as previously described (Pan
et al, 1999) using 0.1 µ g of RNA. Reverse transcription of RNA
from tissues, followed by PCR, was used to detect transforming
growth factor-β 1 (TGF-β 1), tumour necrosis factor-α (TNF-α ),
Fas ligand (FasL) and Fas gene expression. The primers for all
genes were designed according to the published rat complemen-
tary DNA (cDNA) sequences (Suda et al, 1993; Kimura et al,
1994; Farges et al, 1995). The PCR condition consisted of
annealing at 55–60° C (55° C for β -actin, 56° C for TNF-α , 58° C
for Fas/FasL and 60° C for TGF-β 1) for 1 minute. PCR was
performed at 25 cycles for β -actin, 30 cycles for Fas/FasL and
35 cycles for TGF-β 1 and TNF-α . β -actin was amplified as an
internal control to compare relative abundance of PCR products.
The target bands were analysed densitometrically by using a
GS-700 Imaging Densitometer (Bio-Rad, Hercules, CA, USA).
All experiments were repeated more than twice.
Quantitative determination of plasma TGF-β 1 level
After sampling whole blood from the inferior vena cava pre-
operatively and on PODs 1, 3 and 7, plasma was used for enzyme-
linked immunosorbent assays (ELISA) for TGF-β 1. The plasma
TGF-β 1 levels were determined using a PREDICTA TGF-β 1 kit
(Genzyme, Cambridge, MA, USA) for ELISA according to the
manufacturer’s instructions. As a strain control, sampling of
4 non-tumour bearing rats (naive animals) was also performed.
Statistical analysis
All statistical analyses were performed with One-way ANOVA,
and differences between groups were evaluated with Bonferroni
multiple comparison. Data were expressed as the mean ± SD. The
correlation between tumour weights and TGF-β 1 levels wasobtained by simple regression analysis. These were performed
using the SPSS statistical package (Chicago, IL, USA). P values of
< 0.05 were considered to be statistically significant.
RESULTS
Tumour growth, body weight gain and liver
regeneration rate
On POD 7, the intra-hepatic tumour weighed 0.245 ± 0.040 g
(mean ± SD) in the sham. In 30% hepatectomy group, the tumour
weight (0.321 ± 0.058 g) was significantly greater than that of the
sham (P = 0.016), while the tumour (0.156 ± 0.067 g) in 60%
hepatectomy group was significantly suppressed (P = 0.004 vs.
sham) as shown in Figure 1. In all groups, no statistical significant
difference was obtained in body weight gain on POD 7 (Table 1).
The liver regeneration rate (%) in all groups was also similar,
suggesting that DNA synthesis in the regenerating liver almost
completed by restoration of liver volume by 1 week regardless of
the percentage of hepatectomy.
Apoptosis in intra-hepatic tumour
The DNA fragmentation with a ladder pattern was demonstrated in
the tumour portion of three groups obtained on POD 7 (Figure 2A,
lanes 2, 4 and 6). However, no laddering was observed in the DNA
extracted from non-tumour portions in all groups (Figure 2A, lanes
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Table 1. Effects of operation on body weight and liver regeneration
Body weight gain Liver regeneration rate (%)
Sham 1.089± 0.047 5.074± 0.587
30% Hep 1.060± 0.034 4.842± 0.393
60% Hep 1.068± 0.043 4.710± 0.449
Autopsy (POD 7) body weight (g)/pre-operative body weight (g) was defined
as the body weight gain. Autopsy (POD 7) liver weight (g)/pre-operative body
weight (g) × 100 was defined as the liver regeneration rate (%). Hep:
hepatectomy. Each value is expressed as the mean ± SD, n=10 per each
group. No significant difference was observed in all groups. Statistics:
one-way ANOVA
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Figure 1 Effects of hepatectomy on tumour growth. Hep, hepatectomy.
Values represent mean ± SD, n = 10 per each group, *P = 0.016 vs. sham,
†P = 0.004 vs. sham
4.0
3.0
2.0
1.0
0
A
p
o
p
t
o
t
i
c
i
n
d
e
x
(
%
)
Sham 30% Hep 60% Hep
M123456
1000bp
200 bp
AB
Non-tumour portion
Tumour portion
C
Figure 2 (A) Hepatic DNA fragmentation on POD 7. Hep: hepatectomy. The lanes of the gel are as follows. The DNA molecular weight marker (lane M), non-
tumour portion in 60% Hep (lane 1), tumour portion in 60% Hep (lane 2), non-tumour portion in 30% Hep (lane 3), tumour portion in 30% Hep (lane 4), non-
tumour portion in sham (lane 5) and tumour portion in sham (lane 6). (B) TUNEL assay: Apoptotic indices (AI) in tumour portions. AI was calculated according 
to the formula described in the text. Hep: hepatectomy. Values represent mean ± SD. n = 4 per each group, *P < 0.005 vs. 30% hepatectomy and sham. 
(C) TUNEL staining in 60% hepatectomy group. TUNEL-positive tumour cells were localized on the border between the tumour and non-tumour portion in 60%
hepatectomy. Bar: 100 µ mHepatectomy suppresses tumour growth 1099
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1, 3 and 5). Using TUNEL assay with tumour portions from three
groups, the apoptotic index (AI) in 60% hepatectomy was 
2.58 ± 0.49% (mean ± SD), which was significantly higher than
1.08 ± 0.44% in 30% hepatectomy (P = 0.002) and 1.20 ± 0.31%
in the sham (P = 0.004) as shown in Figure 2B. There was no
significant difference of the AI between the 30% hepatectomy and
sham group. The TUNEL-positive tumour cells were localized on
the border between the tumour and non-tumour portion in 60%
hepatectomy (Figure 2C).
Expression of mRNA on POD 7
Expression of TGF-β 1, TNF-α , FasL and Fas mRNA on POD 7
was analysed in the tumour and non-tumour portions of the liver
of all groups as shown in Figure 3. β -actin expression was used
as an internal control and the relative ratio of each gene expres-
sion to β -actin is shown. As for the tumour portion, TGF-β 1,
TNF-α and Fas mRNA in 60% hepatectomy exhibited higher
expression levels than in the 30% hepatectomy and sham group.
Moreover, Fas/FasL ratio (0.70) in 60% hepatectomy was much
higher than the other two groups (0.15 in sham group and 0.27 in
30% hepatectomy). On the other hand, in non-tumour portion
from 60% hepatectomy, the mRNA expression of TGF-β 1 was
higher than those in the 30% hepatectomy and sham group, while
the mRNA levels of TNF-α did not show any significant differ-
ence among three groups. Non-tumour portions in three groups
only faintly, if at all, expressed FasL mRNA although the mRNA
expression of Fas was detectable only in sham group.
Plasma TGF-β 1 protein levels
On POD 7, intra-hepatic tumour weights were inversely correlated
with the values of plasma TGF-β 1 as demonstrated in Figure 4. A
simple regression analysis demonstrated significant correlation
between the TGF-β 1 level and tumour weight (n = 20, r =
0.715,P < 0.001). Plasma TGF-β 1 levels were measured pre-oper-
atively and on PODs 1, 3 and 7 in all groups (n = 4–5) respectively
(Figure 5). TGF-β 1 in 60% hepatectomy was elevated on POD 1
and maintained approximately 2-fold higher levels than in shams
for the subsequent 6 days. On PODs 3 and 7, the values of TGF-β 1
in 60% hepatectomy were 5.75 ± 1.94 ng/ml and 6.30 ± 0.76
ng/ml respectively, which were significantly higher than those
in 30% hepatectomy (3.00 ± 0.71 and 4.10 ± 0.42) and sham
(2.50 ± 0.91 and 3.90 ± 1.14). Pre-operatively, there were no
significant differences in plasma TGF-β 1 levels between tumour
bearing rats and non-tumour bearing rats (n = 4) for strain controls
(data not shown).
DISCUSSION
Little is known as to how hepatectomy is associated with the
tumour growth of such established sites confined to the liver.
Hepatic tumour models in rats generally require the exposure to a
carcinogen (Yano et al, 1995), or the injection of a tumour cell
suspension into the portal vein or into the sub-capsule of the liver,
as previously reported (Mizutani et al, 1992; de Jong et al, 1995;
Slooter et al, 1995; Picardo et al, 1998). However, since these
procedures require a long time for tumour development or easily
make a diffuse lodgement within the liver and peritoneal cavity, it
is difficult to precisely evaluate the effect of hepatectomy on the
established tumour growth in the remaining liver. We have estab-
lished a reliable technique of intra-hepatic tumour implantation by
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Figure 3 Expression of mRNA in tumour and non-tumour portions. Hep,
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Figure 4 Correlation between plasma TGF-β 1 and tumour weight. Assays
were performed in duplicate. Simple regression analysis, n = 20, r = 0.715,
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modifying a technique reported by Yang et al (1992). Using this
model, we demonstrated that the intra-hepatic tumours in 60%
hepatectomy were significantly suppressed as compared with the
sham, while the tumours in 30% hepatectomy were significantly
accelerated.
Based on our TUNEL assay shown in Figure 2, one possible
explanation for the above phenomenon is that 60% hepatectomy
induced more apoptotic cell death of the remaining tumour than
30% hepatectomy or sham. The response of neoplastic cells to
‘death signals’ by far exceeds that of normal hepatocytes (Grasl-
Kraupp et al, 1997). Additionally, certain death factors have also
been defined as being capable of giving a death signal to induce
apoptosis to tumour cells (Patel et al, 1998). In the present study,
the mRNA expression of TGF-β 1, TNFα and Fas/FasL in tumour
portion was compared among groups as these molecules are
involved in initiating the death signals associated with apoptosis in
several types of cells including hepatomas (Lin and Chou, 1992;
Owen-Schaub et al, 1994; Wong and Goeddel, 1994). The mRNA
expression of TGF-β 1, TNFα and Fas in the tumour portion of the
60% hepatectomy group was higher than that in the 30% hepatec-
tomy group. It has also been reported that Fas and TGF-β 1 act
synergistically to induce cell death within tumours (Ashley et al,
1998). Additionally, in our experiments, plasma levels of TGF-β 1
were inversely correlated with tumour weights on POD 7. It has
therefore been strongly speculated that increased TGF-β 1 in the
60% hepatectomy group may lead to cell death including 
Fas-mediated apoptosis for the remaining hepatic tumour.
The volume of the hepatic resection may also answer why
plasma and mRNA levels of TGF-β 1 in the 60% hepatectomy
group were up-regulated compared with the 30% hepatectomy
group. Our results demonstrated that restoration of hepatic volume
occurred by 1 week in both groups subjected to 30% and 60%
hepatic removal, suggesting that the speed or duration of hepatic
regeneration was different between 60% hepatectomy and in 30%
hepatectomy. This may also cause the differences in gene expres-
sion found in hepatocytes of non-tumour portions between 30%
and 60% hepatectomy. In non-tumour portion from 60% hepatec-
tomy, the gene expression of TGF-β 1, which is involved in both
reduced proliferation and apoptosis in hepatocytes, was higher
than that in 30% hepatectomy. This is consistent with another
report that expression of c-myc or c-jun mRNA, which are also
involved in liver regeneration and apoptosis, increased in correla-
tion to the amount of resected liver (Webber et al, 1994).
Therefore, the hepatocytes in normal tissue adjacent to the tumour
after 60% hepatectomy might express and secrete more apoptosis-
related genes and proteins than 30% hepatectomy. This in turn
resulted in the induction of tumour apoptosis by exposing the
tumour to apoptotic inducers such as TGF-β 1 (Fan et al, 1998). In
the present study, plasma levels of TGF-β 1 in 60% hepatectomy
were significantly higher than those in 30% hepatectomy. This
may also suggest a systemic effect of hepatectomy on the growth
of tumour implanted in extra-hepatic sites (Ono et al, 1986).
However, further studies including the possible effect of hepato-
cyte and vascular endothelial growth factors on tumour growth
after varying degrees of hepatic resection are required.
Several reports have also demonstrated that liver regeneration
after hepatic resection might induce a host immune response to the
tumour (Ono et al, 1986; Doerr et al, 1989). Non-parenchymal
cells such as Kupffer cells and pit cells (hepatic natural killer
cells), or other lymphocytes mainly exhibit inhibitory effects on
tumour cells for cytotoxicity (Bayon et al, 1996; Vermijlen et al,
1999). These might have been extremely activated during regener-
ation after major hepatic resection, and it is these activated cells
that may be responsible for the increased TNFα mRNA expression
on the tumour portion of the 60% hepatectomy group in our
present experiments. Moreover, previous studies have described
that tumour cells can escape from host immune attack through the
down-regulation of Fas receptors and the up-regulation of FasL
expression on the tumour site for the development of the malignant
tumour (Higaki et al, 1996; Strand et al, 1996). However, in our
experiments, Fas/FasL ratio in 60% hepatectomy was much higher
than those in the sham and 30% hepatectomy group. These results
suggest that the tumour in 60% hepatectomy animals might have
easily suffered from host immune attack including cytotoxic T
lymphocytes and natural killer cells through Fas-induced
apoptosis.
In conclusion, we have demonstrated that major hepatic resec-
tion might suppress the growth of tumours remaining in the
residual liver. These results may indicate that the extended hepatic
resection for primary HCC is recommended although the choice of
type of liver resection should be based on a balance between the
need for preserving liver function and indications for radical resec-
tion of the tumour. Further studies, including other apoptosis-
related receptors, are underway to elucidate the mechanisms of
tumour apoptosis induced by major hepatic resection.
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